journal article·2019-12

Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer

Xuejun Feng, Hongxian Liu, Xiaojie Chu, Pengyan Sun, Weiwei Huang, Cunbao Liu, Xu Yang, Wenjia Sun, Hongmei Bai, Yanbing Ma

Acta Biomaterialia· Volume 100
Publisher page

Abstract

Recently, interleukin (IL)-33 has been closely associated with a variety of clinical cancers. IL-33 presents both protumorigenic, and less frequently, antitumorigenic functions depending on disease conditions. IL-33 signaling appears to be a possible target for the treatment of applicable tumor diseases. This study aimed to develop an effective approach to intervene in IL-33 functioning in tumors and reveal the immunotherapeutic potential of anti-IL-33 active immunization. Recombinant truncated hepatitis B virus core antigen (HBcAg), presenting mature IL-33 molecules on the surface of virus-like particles (VLPs), was prepared and used to immunize BALB/c mice in a model of murine 4T1 breast cancer. The immunization was performed through either a preventive or therapeutic strategy in two separate studies. Anti-IL-33 immunization with VLPs elicited a persistent and highly titrated specific antibody response and significantly suppressed orthotopic tumor growth in the preventive study and lung metastasis in both studies. The underlying mechanisms might include promoting tumor-specific Th1 and CTL-mediated cellular responses and the expression of the effector molecule interferon-γ (IFN-γ), suppressing T-helper type 2 (Th2) responses, and significantly reducing the infiltration of immunosuppressive Treg (regulatory T) cells and myeloid-derived suppressor cells (MDSCs) into tumor tissues in the immunized mice. In conclusion, anti-IL-33 active immunization employing recombinant VLPs as an antigen delivery platform effectively modified the tumor microenvironment and promoted antitumor immunity, indicating the potential of this approach as a new and promising immunotherapeutic strategy for the treatment of cancers where IL-33 plays a definite protumorigenic role. STATEMENT OF SIGNIFICANCE: Interleukin (IL)-33 is closely associated with a variety of clinical cancers. IL-33 signaling appears to be a possible target for the treatment of applicable tumor diseases. Recombinant truncated hepatitis B virus core antigen (HBcAg), presenting mature IL-33 molecules on the surface of virus-like particles (VLPs), was prepared and used to immunize BALB/c mice in a model of murine 4T1 breast cancer. The immunization was performed through either a preventive or therapeutic strategy in two separate studies. Anti-IL-33 immunization with VLPs elicited a persistent and highly titrated specific antibody response and significantly suppressed orthotopic tumor growth and lung metastasis in both studies. Furthermore, anti-IL-33 active immunization employing recombinant VLPs as an antigen delivery platform effectively modified the tumor microenvironment and promoted antitumor immunity, indicating its potential as a new and promising immunotherapeutic strategy for the treatment of cancers where IL-33 plays a definite protumorigenic role.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: IL-33, ST2, and ILC Pathways · Immune Cell Function and Interaction · Eosinophilic Esophagitis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Serum interleukin-33 levels in patients with gastric cancer10.1007/s10620-011-1760-5 ↗
2. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma10.1593/tlo.12418 ↗
3. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue10.1016/j.anl.2014.08.007 ↗
4. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation10.1172/JCI73742 ↗
5. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer10.7314/APJCP.2013.14.4.2563 ↗
6. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of cot activity10.1038/onc.2014.418 ↗
7. Interleukin-33 expression indicates a favorable prognosis in malignant salivary gland tumors10.1177/1066896916633856 ↗
8. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating Erk and Jnk signaling pathways10.1016/j.molonc.2015.06.004 ↗
9. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma10.1080/00207454.2016.1175441 ↗
10. IL-33 signaling fuels outgrowth and metastasis of human lung cancer10.1016/j.bbrc.2016.09.081 ↗
11. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications10.1177/030006051204000504 ↗
12. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma10.1007/s13277-016-4879-3 ↗
13. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines10.1016/j.immuni.2005.09.015 ↗
14. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex10.4049/jimmunol.0803067 ↗
15. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells10.1073/pnas.0705939104 ↗
16. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-3310.1182/blood-2008-05-157818 ↗
17. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity10.1038/nature08900 ↗
18. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity10.1038/ni.2045 ↗
19. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation10.4049/jimmunol.0901575 ↗
20. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells10.4049/jimmunol.181.1.62 ↗
21. IL-33-activated dendritic cells induce an atypical TH2-type response10.1016/j.jaci.2009.02.026 ↗
22. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells10.1002/ijc.28481 ↗
23. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells10.1080/2162402X.2015.1063772 ↗
24. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms10.1172/JCI77347 ↗
25. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer10.1016/j.bbrc.2014.09.106 ↗
26. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway10.1007/s10620-014-3463-1 ↗
27. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment10.1158/0008-5472.CAN-16-1602 ↗
28. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model10.18632/oncotarget.19786 ↗
29. Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blockingIL-33/ST2 pathway in allergic airway inflammation10.4161/hv.29425 ↗
30. Development of an interleukin (IL)-33 sandwich Elisa kit specific for mature IL-3310.1080/15321819.2016.1179645 ↗
31. IL-33 in T cell differentiation, function, and immune homeostasis10.1016/j.it.2016.03.007 ↗
32. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice10.1038/icb.2016.72 ↗
33. IL-33 increases ST2(+) Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner10.1080/2162402X.2018.1527497 ↗
34. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome10.1126/science.1129139 ↗
35. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses10.4049/jimmunol.1000749 ↗
36. Immunosuppressive networks in the tumour environment and their therapeutic relevance10.1038/nrc1586 ↗
37. Regulatory T cells, tumour immunity and immunotherapy10.1038/nri1806 ↗
38. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis10.1155/2014/686879 ↗
39. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages10.1038/ncomms11385 ↗
40. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy10.1007/s00109-016-1397-0 ↗
41. G.J. Pearce, I.C. Chikanza, Targeting tumour necrosis factor in the treatment of rheumatoid arthritis, Biodrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy15(3) (2001) 139–49.10.2165/00063030-200115030-00001 ↗
42. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment10.2174/156800911793743583 ↗
43. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer10.1200/JCO.2007.11.5980 ↗
44. Therapeutic vaccines for cancer: an overview of clinical trials10.1038/nrclinonc.2014.111 ↗
45. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment10.1038/ncomms13589 ↗
46. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population10.1038/ncomms14919 ↗
47. Disease-associated functions of IL-33: the new kid in the IL-1 family10.1038/nri2692 ↗
48. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice10.1016/j.canlet.2013.03.002 ↗
49. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-3310.1038/srep30555 ↗
50. Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-gamma10.1007/s12032-014-0143-0 ↗
51. Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model10.1016/j.vaccine.2015.03.086 ↗
52. The role of IL-33-Dependent inflammation in the tumor microenvironment
53. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells10.4049/jimmunol.1401344 ↗